MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on January 10, 2008; DOI: 10.1124/mol.107.043844


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.043844v1
73/4/1072    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weinglass, A. B.
Right arrow Articles by Garcia, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weinglass, A. B.
Right arrow Articles by Garcia, M. L.


Received for publication November 27, 2007.
Revised January 9, 2008.
Accepted for publication January 9, 2008.

MDCKII cells: a pharmacologically validated system for NPC1L1-mediated cholesterol uptake

Adam B. Weinglass 1*, Martin G. Kohler 1, Emmanuel O. Nketiah 1, Jessica Liu 1, William Schmalhofer 1, Anu Thomas 1, Brande Williams 1, Lindsey Beers 1, Lauren Smith 1, Mike Hafey 1, Kelly Bleasby 1, Joseph Leone 1, Yui Sing Tang 1, Matthew P. Braun 1, Feroze Ujjainwalla 1, Margaret E. McCann 1, Gregory J. Kaczorowski 1, Maria L. Garcia 1

1 Merck & Co.

* Address correspondence to: E-mail: adam_weinglass{at}merck.com

Abstract

Absorption of dietary cholesterol in the proximal region of the intestine is mediated by Niemann-Pick C1-like protein (NPC1L1) and is sensitive to the cholesterol absorption inhibitor, ezetimibe (EZE). While a correlation exists between EZE binding to NPC1L1 in vitro and in vivo efficacy, the precise nature of interaction(s) between NPC1L1, EZE and cholesterol remain unclear. Here, we analyze the direct relationship between EZE-analog binding to NPC1L1 and its influence on cholesterol influx in a novel in vitro system. Using the EZE-analog, [3H]AS, an assay that quantitatively measures the expression of NPC1L1 on the cell surface has been developed. Interestingly, while two cell lines (CaCo-2 and HepG2), commonly used for studying NPC1L1-dependent processes, express almost undetectable levels of NPC1L1 at the cell surface, polarized Madin-Darby Canine Kidney (MDCKII) cells endogenously express 4 x 105 [3H]AS sites/cell under basal conditions. Depleting endogenous cholesterol with the HMG CoA reductase inhibitor lovastatin leads to a 2-fold increase in the surface expression of NPC1L1 supporting the contention that MDCKII cells respond to changes in cholesterol homeostasis by up-regulating a pathway for cholesterol influx. However, a significant increase in surface expression levels of NPC1L1 is necessary to characterize a pharmacologically sensitive, EZE-dependent pathway of cholesterol uptake in these cells. Remarkably, the affinity of EZE-analogs for binding to NPC1L1 is almost identical to the IC50 blocking cholesterol flux through NPC1L1 in MDCKII cells. Mechanistically, these observations support the contention that EZE-analogs and cholesterol share the same/overlapping binding site(s) or are tightly coupled through allosteric interactions.


Key words: Func. analysis receptor/ion channel mutants, Receptor binding studies, Cholesterol metabolism/lipoproteins


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
A. B. Weinglass, M. Kohler, U. Schulte, J. Liu, E. O. Nketiah, A. Thomas, W. Schmalhofer, B. Williams, W. Bildl, D. R. McMasters, et al.
Extracellular loop C of NPC1L1 is important for binding to ezetimibe
PNAS, August 12, 2008; 105(32): 11140 - 11145.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics